The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EBMT 2025 | The impact of FLT3-inhibitor maintenance post alloSCT in AML with FLT3-ITD and NPM1/DNMT3A mutations
In this video, Dennis Kim, MD, PhD, Princess Margaret Cancer Centre, Toronto, Canada, discusses the findings of a study assessing the impact of FLT3-inhibitor maintenance post allogeneic stem cell transplantation (alloSCT) in patients with acute myeloid leukemia (AML) with FLT3-ITD and associated NPM1/DNMT3A mutations. This interview took place at the 51st Annual Meeting of the EBMT in Florence, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So what we have done is that we have looked at the impact of FLT3 inhibitor prophylaxis in patients who received allogeneic stem cell transplant. After the allogeneic transplant, we would like to see whether it’s beneficial or not. So we have collected 439 patients’ data across the world, and what we have found is that definitely FLT3 inhibitor is beneficial to prevent the relapse...
So what we have done is that we have looked at the impact of FLT3 inhibitor prophylaxis in patients who received allogeneic stem cell transplant. After the allogeneic transplant, we would like to see whether it’s beneficial or not. So we have collected 439 patients’ data across the world, and what we have found is that definitely FLT3 inhibitor is beneficial to prevent the relapse.
But also at the same time, out of these patients, it looked like if they have a FLT3-ITD, NPM1, and DNMT3A, their outcome is way worse, even after the allo-transplant. That’s number one finding that we found. And number two is that however, even if they have FLT3-ITD, NPM1, and DNMT3A, which is kind of a worse triple mutation; however, whenever they get a FLT3 inhibitor maintenance treatment, their outcome is going to be mitigated. So they will have a similar kind of outcome in comparison to the other group, those that have a favorable outcome. So the FLT3 inhibitor will be helpful to improve their outcome, even the patient having a FLT3-ITD, DNMT3A, and NPM1 mutation. That is our message in our study.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Honoraria: Sanofi, Novartis, Astellas, Pfizer, Sankyo-Daichi, Jazz.
